Phase 10

ZimVie Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024

We are optimistic about the future of ZimVie as a purely dental focused company with a strong capital structure.”

Key Points: 
  • We are optimistic about the future of ZimVie as a purely dental focused company with a strong capital structure.”
    Fourth Quarter 2023 Financial Results: Continuing Operations
    Third party net sales for the fourth quarter of 2023 were $113.1 million, a decrease of 2.4% on a reported basis and (3.6%) on a constant currency[1] basis, versus the fourth quarter of 2022.
  • Net loss for the fourth quarter of 2023 was ($22.2) million, a change of ($6.8) million versus a net loss of ($15.4) million in the fourth quarter of 2022, and as a percentage of net sales was (19.6%).
  • Basic and diluted EPS were ($0.83) and adjusted diluted EPS[1] was $0.10 for the fourth quarter of 2023.
  • Fourth Quarter 2023 Financial Results: Discontinued Operations
    Third party net sales from Discontinued Operations for the fourth quarter of 2023 were $100.5 million, a decrease of 10.6% on a reported basis and 10.6% on a constant currency[1] basis, versus the fourth quarter of 2022.

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024

-- Significant Progress in Establishing Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, Including Expanded Collaboration with Lonza --

Key Points: 
  • ET / 1:30 p.m. PT --
    SAN CARLOS, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Additionally, as part of ongoing Chemistry, Manufacturing and Controls (CMC)-focused discussions, Vaxcyte received encouraging input from the FDA regarding the VAX-24 adult licensure requirements.
  • The six-month safety data from both studies showed safety and tolerability results for VAX-24 similar to PCV20 at all doses studied.
  • Vaxcyte will host a conference call and webcast to discuss this announcement today, February 27, 2024, at 4:30 p.m.

Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

Retrieved on: 
Friday, February 16, 2024

The Staff Determination has no immediate effect and will not immediately result in the suspension of trading or delisting of the Company’s securities.

Key Points: 
  • The Staff Determination has no immediate effect and will not immediately result in the suspension of trading or delisting of the Company’s securities.
  • The Company’s request for a hearing before the Nasdaq Hearing Panel to appeal the Staff Determination must be made no later than 4:00 p.m. Eastern Time on February 20, 2024.
  • According to the Staff Determination, hearings are typically scheduled to occur approximately 30-45 days after the date of a company’s hearing request.
  • Following the hearing, the Hearings Panel will issue a decision, which the Company may further appeal to the Nasdaq Listing Council for review.

Sylvamo Generates Strong Operating Cash Flow, Returns $127 Million in Cash to Shareowners in 2023

Retrieved on: 
Thursday, February 15, 2024

Last year, we invested $210 million to strengthen our low-cost assets and acquired a 500,000-ton uncoated freesheet mill in Nymolla, Sweden, for $167 million.

Key Points: 
  • Last year, we invested $210 million to strengthen our low-cost assets and acquired a 500,000-ton uncoated freesheet mill in Nymolla, Sweden, for $167 million.
  • In 2023, this mill generated strong cash flow, benefiting from the $40 million pulp mill modernization project completed just before the acquisition.
  • By the end of 2023, we exhausted our initial $150 million share repurchase program authorization and have approximately $150 million remaining on our September 2023 authorization.
  • We will continue to return substantial amounts of cash to shareowners and look for opportunities to repurchase shares at attractive prices.

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

Retrieved on: 
Thursday, January 4, 2024

-- Enrollment in Ongoing VAX-24 Infant Phase 2 Study Continues to Progress; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 --

Key Points: 
  • Vaxcyte’s carrier-sparing PCV franchise candidates, including VAX-24, a 24-valent PCV proceeding to Phase 3, and VAX-31, the Company’s next-generation 31-valent PCV, are being studied for the prevention of invasive pneumococcal disease (IPD).
  • The VAX-24 Phase 2 infant study continues to enroll participants in the second and final stage of the study.
  • This is a randomized, observer-blind, dose-finding two-stage clinical study evaluating the safety, tolerability and immunogenicity of VAX-24 in healthy infants.
  • Topline safety, tolerability and immunogenicity data from the ongoing adult Phase 1/2 study in the third quarter of 2024.

EQS-News: Abivax 2024 Financial Communication Calendar

Retrieved on: 
Thursday, January 4, 2024

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • PARIS, France, January 4, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today publishes its 2024 financial communication calendar.
  • 2023 Annual Business and Financial Report (as of December 31, 2023)
    2024 Half-Year Business and Financial Report (as of June 30, 2024)
    Third Quarter 2024 Financial Information (as of September 30, 2024)

Abivax 2024 Financial Communication Calendar

Retrieved on: 
Thursday, January 4, 2024

PARIS, France, January 4, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today publishes its 2024 financial communication calendar.

Key Points: 
  • PARIS, France, January 4, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today publishes its 2024 financial communication calendar.
  • 2023 Annual Business and Financial Report (as of December 31, 2023)
    2024 Half-Year Business and Financial Report (as of June 30, 2024)
    Third Quarter 2024 Financial Information (as of September 30, 2024)

Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023

Retrieved on: 
Thursday, November 23, 2023

Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that that it will issue its Third Quarter 2023 Financial Results on November 29, 2023.

Key Points: 
  • Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that that it will issue its Third Quarter 2023 Financial Results on November 29, 2023.
  • Participants are required to register in advance of the conference using the link provided below.
  • Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.
  • Participants may also use the call me feature instead of dialing the nearest dial in number.

OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023

Third Quarter 2023 Financial Results of OpGen, Inc.

Key Points: 
  • Third Quarter 2023 Financial Results of OpGen, Inc.
    Total revenue for the third quarter of 2023 was approximately $0.70 million compared to the Company’s revenue of approximately $0.45 million in the third quarter of 2022.
  • Total operating expenses decreased in the third quarter of 2023 to approximately $4.26 million compared to approximately $13.96 million for the third quarter of 2022 primarily due to the Company’s goodwill impairment charge of $6.98 million recorded in the third quarter of 2022.
  • Cash and cash equivalents were approximately $0.29 million as of September 30, 2023, compared with approximately $7.44 million as of December 31, 2022.
  • In October 2023, OpGen discontinued its FDA cleared Acuitas AMR Gene Panel diagnostic test.

Omniq Schedules Third Quarter 2023 Earnings Release After the Market Close on Monday, November 13th

Retrieved on: 
Thursday, November 9, 2023

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- --OMNIQ Corp. (NASDAQ: OMQS) a provider of Supply Chain and Artificial Intelligence (AI)-based solutions, will release Third Quarter 2023 Earnings after the market close on Monday, November 13th, 2023.

Key Points: 
  • SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- --OMNIQ Corp. (NASDAQ: OMQS) a provider of Supply Chain and Artificial Intelligence (AI)-based solutions, will release Third Quarter 2023 Earnings after the market close on Monday, November 13th, 2023.
  • The announcement will be followed by a live earnings call with management the following morning, Tuesday November 14th at 8:30am EST.
  • To access the live webcast, please click on this webcast link https://www.webcaster4.com/Webcast/Page/2310/49470
    To participate in the call by phone, dial 877-545-0523 approximately five minutes prior to the scheduled start time.
  • A replay of the teleconference will be available until Thursday, December 14, 2023 and may be accessed by dialing 877-481-4010. International callers may dial 919-882-2331.